pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Cobenfy
drug
save

(trospium chloride + xanomeline tartrate)

Marketedupdated 6mo ago
by Bristol-Myers Squibb Co
Approved
community read0 votes

indications

investigational
Schizophrenia

all catalysts(0)

nothing on the calendar yet

Patent cliff

source: FDA Orange Book
first barrier falls
Sep 26, 2029
~2.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (33)

  • Oct 29, 2039formulationUS 12558317
  • Oct 29, 2039formulationUS 12558317
  • Oct 29, 2039formulationUS 12558317
  • Sep 27, 2039formulationUS 10925832
  • Sep 27, 2039formulationUS 10925832
  • Sep 27, 2039formulationUS 10925832
  • Sep 27, 2039formulationUS 10933020
  • Sep 27, 2039formulationUS 10933020
  • Sep 27, 2039formulationUS 10933020
  • Sep 27, 2039method-of-use (U-3513)US 11452692
  • Sep 27, 2039method-of-use (U-3513)US 11452692
  • Sep 27, 2039method-of-use (U-3513)US 11452692
  • Sep 27, 2039method-of-use (U-3513)US 11471413
  • Sep 27, 2039method-of-use (U-3513)US 11471413
  • Sep 27, 2039method-of-use (U-3513)US 11471413
  • Sep 27, 2039formulationUS 11890378
  • Sep 27, 2039formulationUS 11890378
  • Sep 27, 2039formulationUS 11890378
  • Jul 21, 2030formulationUS 102386433.7y
  • Jul 21, 2030formulationUS 102386433.7y
  • Jul 21, 2030formulationUS 102386433.7y
  • Jul 21, 2030method-of-use (U-3513)US 102653113.7y
  • Jul 21, 2030method-of-use (U-3513)US 102653113.7y
  • Jul 21, 2030method-of-use (U-3513)US 102653113.7y
  • Jul 21, 2030method-of-use (U-3513)US 103691433.7y
  • Jul 21, 2030method-of-use (U-3513)US 103691433.7y
  • Jul 21, 2030method-of-use (U-3513)US 103691433.7y
  • Jul 21, 2030formulationUS 103691443.7y
  • Jul 21, 2030formulationUS 103691443.7y
  • Jul 21, 2030formulationUS 103691443.7y
  • Jul 21, 2030method-of-use (U-3513)US 106953393.7y
  • Jul 21, 2030method-of-use (U-3513)US 106953393.7y
  • Jul 21, 2030method-of-use (U-3513)US 106953393.7y

FDA exclusivities (3)

  • Sep 26, 2029NCENew Chemical Entity (5y)2.9y
  • Sep 26, 2029NCENew Chemical Entity (5y)2.9y
  • Sep 26, 2029NCENew Chemical Entity (5y)2.9y

News(10)

  • CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions
    At the Clinical Trials on Alzheimer’s Disease Conference, BMS finally revealed early data for its Alzheimer’s disease psychosis trials of KarXT, marketed as Cobenfy in schizophrenia.
    biospace · 1d ago
  • Alzheimer’s field looks beyond amyloid as biopharma converges at CTAD 2026
    This week, biopharma companies including Biogen, Bristol Myers Squibb and Roche are in Boston with new data on their efforts to tackle Alzheimer’s disease.
    biospace · 3d ago
  • Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties
    Novo views the medicine, acquired in a billion-dollar deal, as a future blockbuster. Meanwhile, a pair of startups forged an RNA editing pact and Astellas lined up two new trials in pancreatic cancer.
    biopharma_dive · 6d ago
  • Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push
    Addex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for tr…
    biospace · 7d ago
  • BMS R&D head to depart amid restructure
    Bristol Myers Squibb is combining all research and development efforts under one leader as pressure rises to replenish its pipeline.
    biospace · 7d ago
  • Neurosterix pulls in $105M for schizophrenia drug, taps Cobenfy vets
    Neurosterix, which is reuniting some key figures behind Cobenfy, has corralled $105 million in a Series B to fund its lead schizophrenia candidate that hits one of the targets of Bristol Myers Squi…
    endpoints · 7d ago
  • With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys
    After emraclidine’s schizophrenia fail and Cobenfy’s laggard launch, it’s too early to know who made the better buy: AbbVie, in its $8.7 billion Cerevel takeover in late 2023, or Bristol Myers Squi…
    biospace · 10d ago
  • BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
    In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma…
    biospace · 21d ago
  • Pathos inks BMS, Tempus collabs to apply agentic AI in Alzheimer's clinical development
    Pathos AI has signed two new collaboration deals aimed at developing drugs for neurological conditions such as Alzheimer's disease, one with pharma giant Bristol Myers Squibb and another with Tempu…
    fiercebiotech · 1mo ago
  • BMS’ Phase 3 win for lung drug clouded by high-dose miss
    A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awa…
    biospace · 1mo ago
view all news mentions →
brand
Cobenfy
generic
(trospium chloride + xanomeline tartrate)
indication
Psychosis
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 8h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?